(RTTNews) - Pliant Therapeutics, Inc. (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin ...

“However, PLN asserts that the critical phase has not passed,” said PLN corporate communication VP Agung Murdifi in a statement on January 3. The additional 3.2 million coal supply commitment is ...

As a subscriber, you can gift 3 to 5 articles each month that anyone can read—no subscription needed! State-owned electricity company PLN is gradually reducing the use of diesel-fueled power ...

Following the successful completion of this study, PLN-1474 has been transferred to Novartis. The Phase 1 trial of PLN ... of PLN-1474 and up to three integrin research targets.

"We are now progressing with Phase 1b evaluation of PLN-74809 to assess its effects on ... Monday, May 20, 2019, 3:45 p.m. – 4:00 p.m. CST ...

The Phase 1 trial of PLN-101095 is currently enrolling the fourth of five potential cohorts. The fourth cohort is evaluating PLN-101095 at 1000 mg, three times daily (TID). Slides accompanying ...

Feb. 28, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced positive data from its expanded PLN-74809 Phase 1b proof-of-mechanism trial. PLN-74809 demonstrated clear ...

INTEGRIS-IPF is a randomized, double-blind, placebo-controlled Phase ... of PLN-74809. The secondary endpoint is an assessment of its pharmacokinetics. PLN-74809 was well tolerated at all three ...

As a subscriber, you can gift 3 to 5 articles each month ... opportunities such as CFPP phase-down projects to Chinese investors is an important step for PLN as coal phasing down is a relatively ...

March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial ...